In this edition of OncTimes Talk we’re taking a look at: extending life in patients with metastatic hormone-sensitive prostate cancer by adding a third drug to standard two-drug regimens.

In the randomized Phase III ARASENS trial—just published in the New England Journal of Medicine—the androgen receptor inhibitor, darolutamide, was compared with placebo when added to gold-standard two-drug therapy.

Peter Goodwin visited the Royal Marsden Hospital in London UK to meet one of the ARASENS study investigators: Consultant Clinical Oncologist Vincent Khoo.